News & Updates

Chest X-ray Plus Artificial Intelligence Can Predict Worst Outcomes for COVID-19-Positive Patients

05/17/2021

Excerpt from the Press Release: Computer program can accurately predict 80 percent of cases where COVID-19 patients will develop life-threatening conditions within four days. Chest X-rays aren’t just for diagnosing COVID-19. Newly published research now shows that these images can be part of a system that accurately predicts which patients will develop life-threatening conditions within…

Read More

Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma

05/17/2021

Excerpt from the Press Release: SAN CARLOS, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that the Journal of Clinical Oncology has published a manuscript of clinical data for Cohort 2 in the C-144-01…

Read More

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients

05/14/2021

Excerpt from the Press Release: WALNUT CREEK, CA and LONDON, UK / ACCESSWIRE / May 3, 2021 / Vivacitas Oncology, Inc. (“Vivacitas” or the “Company“), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group (“IAG”), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and…

Read More

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor

05/14/2021

Excerpt from the Press Release: SAN MATEO, Calif., May 4, 2021 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next…

Read More

Key Changes In The Revised EMA Guidance On Clinical Trials During COVID

05/13/2021

Excerpt from the Article: In February, the European Medicines Agency (EMA) released the fourth version of its Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic. As the pandemic continues to impact clinical research worldwide, these updated guidelines reflect the EMA’s evolving stance, clarifying questions raised by previous versions and taking into account…

Read More

Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model

05/13/2021

Excerpt from the Press Release: WAYNE, Pa., May 4, 2021 /PRNewswire/ — In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at Moffitt Cancer Center, Sarin Lab at the Stanford University School of Medicine and NFlection Therapeutics demonstrate positive efficacy in preclinical models for the…

Read More

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

05/13/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2…

Read More

RSIP Vision Launches an Advanced AI-Based Tool for Prostate MRI and Ultrasound Registration Enabling Precise Navigation in Key Procedures

05/13/2021

Excerpt from the Press Release: TEL AVIV, Israel & SAN JOSE, Calif.–(BUSINESS WIRE)–RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool. The tool’s fully automated, deep learning-based capabilities provide a robust method that utilizes a registered MRI scan…

Read More

Protein ‘signature’ linked to severe COVID-19 outcomes identified, Mass General Hospital study says

05/12/2021

Excerpt from the Article: Massachusetts General Hospital researchers have identified what’s known as a protein “signature” linked to severe health outcomes including death for people who contract COVID-19, according to an article published Tuesday in the Harvard Gazette. Researchers led by Dr. Marcia Goldberg, an MGH infectious disease expert, and Dr. Michael Filbin, an attending physician…

Read More

Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

05/12/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of data that further validate the potential of its mass cytometry technologies, CyTOF® and Imaging Mass Cytometry™ (IMC™), to provide new approaches to…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives